Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Kyowa Kirin Co (($KYKOF)) announced an update on their ongoing clinical study. Study Overview: Kyowa Kirin Co. has initiated a Phase 1 clinical ...

Patients treated with mogamulizumab showed a trend toward improved OS compared to those not receiving mogamulizumab across risk-stratified groups according to the new Cutaneous Lymphoma International ...

A study published in Cancer Discovery finds that combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body's natural response to viral infections, shows promising results in ...

Prime researchers found that the CAR T cohort had a significantly higher average total cost of care compared with the BiTE cohort: $702,000 vs. $372,000. Among the studied therapies, drug costs were ...

Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma. Treatment with the CAR T-cell therapy Yescarta ...

“Utilizing real-world data, technology, strategic solutions, and cross-departmental partnerships will help ensure equitable access, so the right member receives the right drug at the right time and ...

The integration of Bruton tyrosine kinase (BTK) inhibitors into first-line treatment regimens, in combination with ...

Dr. Matthew Matasar discusses why stem cell transplant is still a standard, life-saving option in blood cancers and how CAR-T ...